$Lexaria Bioscience (LEXX.US)$Reuters· 4 mins ago Lexaria Bioscience: Dehydratech-Processed Rybelsus Evidenced Trend Toward Higher Overall Absorption Vs Rybelsus Not Processed With Dehydratech
Lexaria Bioscience Corp. Reports Positive Interim Body Weight Results from Diabetes Animal Study. Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW), a global innovator in drug delivery platforms, recently announced interim results from the first four weeks of dosing in its ongoing diabetes animal study, WEIGHT-A24-1 (the "Study").$Lexaria Bioscience (LEXX.US)$ https://stockregion.app/p/bioscience-company-reports-positive-6c7
Lexaria Bioscience股票討論區
Lexaria第二個GLP-1人體試驗顯示在DehydraTECH處理的Rybelsus(R)口服膠囊中沒有任何不良事件。
Lexaria Bioscience corp(NASDAQ:LEXX)宣布了其第二個GLP-1人體試驗(GLP-1-H24-2)在DehydraTECH處理的Rybelsus®口服膠囊的積極結果。主要發現包括:
1. 卓越的耐受性:服用DehydraTECH處理的Rybelsus®膠囊的9名參與者中沒有出現不良事件,相較於......
更大的圖片: tradingview.com...
$Lexaria Bioscience (LEXX.US)$
Mt Newswires· 1 分鐘前
Lexaria Bioscience: Dehydratech-Processed Rybelsus Evidenced Trend Toward Higher Overall Absorption Vs Rybelsus Not Processed With Dehydratech
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW), a global innovator in drug delivery platforms, recently announced interim results from the first four weeks of dosing in its ongoing diabetes animal study, WEIGHT-A24-1 (the "Study"). $Lexaria Bioscience (LEXX.US)$
https://stockregion.app/p/bioscience-company-reports-positive-6c7
Lexaria的糖尿病動物研究取得積極的中期體重結果
Lexaria Bioscience corp.(納斯達克:LEXX)報告其糖尿病動物研究WEIGHt-A24-1取得積極的中期結果。經過28天的投藥,DehydraTECH處理的藥物治療顯示體重增加減少或體重減輕。關鍵發現包括:
1. DehydraTECH-CBD配方3和DehydraTECH-liraglutide分別產生最大的體重減輕:分別為-1.50%和-1.58%。
2. De...
Accesswire· 3 分鐘前
暫無評論